Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients

This study showed that GC‐MS‐based metabolomics could provide a promising strategy for complementary diagnosis of CML and offer a new insight to monitor therapeutic responses of TKI in CML patients. Notably, myristic acid and glycerol may serve as a biomarker for characterizing CML patients and for the therapeutic responses of TKI.
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research